The Power and the Problem
Gene editing gives humanity the ability to rewrite the code of life. CRISPR-Cas9, base editing, and prime editing can correct disease-causing mutations, disable pathogenic genes, and potentially enhance biological traits. The first CRISPR therapy, Casgevy, is already treating patients with sickle cell disease. Dozens more therapies are in clinical trials.
But the same technology that can cure a child of a fatal blood disorder can, in principle, be used to modify human embryos, alter the traits of future generations, or create genetic advantages available only to the wealthy. The ethical questions are not theoretical. They are urgent, contested, and largely unresolved.
Somatic Editing: The Easier Case
Somatic gene editing modifies cells in a living person's body -- blood cells, liver cells, retinal cells. The changes affect only the treated individual and are not inherited by their children. From an ethical standpoint, somatic editing is broadly comparable to any other medical intervention: it requires informed consent, demonstrated safety and efficacy, and regulatory approval.
Most ethicists, clinicians, and regulatory bodies agree that somatic gene editing for serious diseases is ethically permissible when it meets these standards. The approval of Casgevy for sickle cell disease in 2023, and the growing pipeline of CRISPR-based therapies for conditions like transthyretin amyloidosis and hereditary angioedema, represents this consensus in action.
The harder questions begin when the editing moves upstream -- to the germline.
Germline Editing: Rewriting the Future
Germline editing modifies eggs, sperm, or embryos. Any changes made at this stage become part of the individual's genome and will be passed to all of their descendants. This is the ethical fault line that divides the gene editing debate.
Proponents argue that germline editing could eventually eliminate devastating genetic diseases at their source. Instead of treating each generation of children born with cystic fibrosis or Huntington's disease, we could remove the disease-causing variant from a family lineage permanently.
Critics raise three fundamental objections:
Consent. Future generations who inherit edited genes had no say in the modification. Unlike a patient choosing somatic therapy, the descendants of germline editing are subjects without agency. This violates a core principle of medical ethics.
Unpredictable consequences. Human genetics is complex. Genes interact with each other and with the environment in ways we do not fully understand. A germline edit that appears beneficial in one context could have harmful effects across generations, in different genetic backgrounds, or under different environmental conditions. The CCR5 gene, targeted by He Jiankui, plays roles in immune function beyond HIV resistance -- its deletion may increase susceptibility to West Nile virus and influenza.
Irreversibility. Once a germline edit enters the human gene pool, it cannot be recalled. There is no undo button for a modification that propagates through reproduction across centuries.
The He Jiankui Controversy
In November 2018, Chinese biophysicist He Jiankui shocked the world by announcing that he had used CRISPR to edit the CCR5 gene in human embryos, resulting in the birth of twin girls known as Lulu and Nana. A third child was born from the same experiments in 2019.
The scientific community's response was swift and almost unanimously condemnatory. He's experiment violated established ethical guidelines on multiple fronts:
- He did not obtain proper institutional ethics approval.
- The informed consent process for the parents was deeply flawed.
- The medical justification was weak -- HIV can be prevented through existing, far less risky methods.
- The editing itself was imprecise, creating mosaic patterns where some cells were edited and others were not.
- He failed to adequately address off-target effects.
He Jiankui was convicted by a Chinese court in 2019 and sentenced to three years in prison. He was released in 2022 and has since attempted to re-enter the scientific community, a prospect that many researchers view with deep unease.
The case served as a wake-up call. It demonstrated that the technical barriers to germline editing were lower than many had assumed, and that existing governance structures were insufficient to prevent rogue experiments. The three children from He's experiments will carry edited genes for their entire lives, and the long-term health consequences remain unknown.
The Designer Baby Debate
The most visceral public fear around gene editing is the prospect of "designer babies" -- using genetic modification to select or enhance traits like intelligence, athletic ability, appearance, or personality.
Several realities temper this concern in the near term. Most traits that people might want to enhance are polygenic, influenced by hundreds or thousands of genetic variants as well as environmental factors. We cannot currently predict complex traits from genotype with useful accuracy, let alone engineer them reliably. The science is simply not there.
But the concern is not baseless. As our understanding of genetics improves and as editing tools become more precise, the technical barriers will lower. The real question is whether social, legal, and ethical barriers will hold.
Critics warn of a slippery slope: once germline editing for disease prevention is normalized, the line between therapy and enhancement will blur. Is editing out a gene variant that increases Alzheimer's risk by 5 percent treating disease or enhancing cognitive resilience? What about a variant associated with slightly below-average height? The boundary between "normal" and "diseased" is not a bright line -- it is a gradient that different cultures, physicians, and patients will draw differently.
If genetic enhancement ever becomes possible, the equity implications are staggering. A world where wealthy families can purchase genetic advantages for their children while others cannot would entrench inequality at the biological level.
The Regulatory Landscape
International regulation of gene editing is a patchwork with significant gaps.
United States: The FDA regulates gene therapies as biological products. Congressional riders have prohibited the FDA from reviewing applications involving germline editing of human embryos. Basic research on human embryos is permitted with private (but not federal) funding.
United Kingdom: The Human Fertilisation and Embryology Authority permits research on human embryos up to 14 days. Clinical germline editing is prohibited. The UK has been relatively progressive on somatic gene therapy research.
China: Following the He Jiankui scandal, China strengthened regulations and introduced criminal penalties for unauthorized human embryo editing. However, enforcement capacity and transparency remain concerns.
European Union: Most EU member states prohibit germline editing under the Oviedo Convention on human rights and biomedicine, though not all states have ratified it. The EU has historically taken a precautionary approach to genetic modification.
Global coordination: The World Health Organization released an advisory governance framework in 2021 recommending a global registry for human genome editing research, whistleblower protections, and international regulatory cooperation. The framework is non-binding but represents the most serious international effort to date.
The fundamental problem is that biology does not respect national borders. An experiment banned in one country can be conducted in another. Without binding international agreements, governance will remain reactive rather than preventive.
Equitable Access: The Justice Question
Even setting aside germline editing, the ethics of somatic gene therapy raise urgent justice concerns. Casgevy costs approximately $2.2 million per treatment. The gene therapy Zolgensma costs $2.1 million. These prices reflect complex manufacturing, small patient populations, and the economics of pharmaceutical development -- but they also mean that life-saving treatments are available only to patients in wealthy countries with robust insurance systems.
Sickle cell disease, one of the first conditions treatable by CRISPR, disproportionately affects people in sub-Saharan Africa -- precisely the region with the least capacity to deliver expensive gene therapies. If the genetic revolution benefits only the global North, it will deepen health disparities rather than reduce them.
Organizations like the Innovative Genomics Institute and the Gates Foundation are investing in approaches to make gene editing therapies more affordable and deliverable in low-resource settings. But the structural incentives of pharmaceutical markets work against equitable access, and the problem will grow as more therapies reach the market.
Drawing the Line
Where should we draw the line? The emerging consensus, fragile and contested as it is, includes several principles:
- Somatic gene editing for serious diseases is ethically permissible under standard regulatory frameworks.
- Germline editing for reproduction should not proceed until safety can be demonstrated and broad societal consensus is reached.
- Enhancement applications are premature and require extensive public deliberation before any clinical use.
- Equity must be a central consideration, not an afterthought.
- Governance must be international, binding, and enforceable.
These principles are easier to state than to implement. The line between therapy and enhancement is blurry. International consensus is hard to achieve and harder to enforce. And the technology continues to advance faster than the governance frameworks designed to regulate it.
The ethics of gene editing are not a problem to be solved once and filed away. They are an ongoing negotiation between human aspiration and human caution, between the desire to alleviate suffering and the wisdom to recognize the limits of our foresight. The line must be drawn -- and then redrawn, and drawn again, as the science evolves and society learns.
